Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816853 | 0.95 | FBP1 (0.43) | FBP1S1PR4CHIT1ALDH1A1GAA | |
| SCHEMBL2812983 | 0.90 | FBP1 (0.47) | FBP1S1PR4ALDH1A1GAAKMT2A | |
| SCHEMBL2817159 | 0.87 | FBP1 (0.48) | FBP1GAANPC1RAB9AKMT2A | |
| SCHEMBL3992247 | 0.87 | FBP1 (0.45) | FBP1 | |
| SCHEMBL2815726 | 0.85 | FBP1 (0.46) | FBP1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL3989886 | 0.82 | FBP1 (0.45) | FBP1NPC1RAB9AKMT2A | |
| SCHEMBL3993827 | 0.82 | FBP1 (0.45) | FBP1GAANPC1RAB9AKMT2A | |
| SCHEMBL2812988 | 0.82 | SMN1; SMN2 (0.45) | FBP1ALDH1A1RAB9AKMT2A | |
| SCHEMBL2814384 | 0.82 | FBP1 (0.46) | FBP1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL2816512 | 0.81 | FBP1 (0.46) | FBP1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | FBP1 2186/4885CACNA1C 3584/4885SCN5A 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.